We are live on ! Find out more
EAM

Eventide Asset Management Portfolio holdings

AUM $6.05B
1-Year Est. Return 76.64%
This Fund
S&P 500
This Quarter Est. Return
+16.69%
1 Year Est. Return
+76.64%
3 Year Est. Return
+247.17%
5 Year Est. Return
+285.6%
10 Year Est. Return
+2,546.71%
AUM
$1.64B
AUM Growth
+$3.83M
Cap. Flow
-$183M
Cap. Flow %
-11.16%
Top 10 Hldgs %
30.28%
Holding
138
New
10
Increased
27
Reduced
20
Closed
13

Top Buys

Rank Stock Value
1
AYI icon
Acuity Brands
AYI
+$21.3M
2
ROL icon
Rollins
ROL
+$14M
3
SNA icon
Snap-on
SNA
+$13.9M
4
DOOR
MASONITE INTERNATIONAL CORP
DOOR
+$13.6M
5
WSO icon
Watsco Inc
WSO
+$12.9M

Top Sells

Rank Stock Value
1
FSLR icon
First Solar
FSLR
+$27.4M
2
CELG
Celgene Corp
CELG
+$24.6M
3
CCI icon
Crown Castle
CCI
+$21.2M
4
SYNA icon
Synaptics
SYNA
+$21M
5
CBI
Chicago Bridge & Iron Nv
CBI
+$16.9M

Sector Composition

Rank Sector Weight
1 Healthcare 35.44%
2 Technology 16.99%
3 Consumer Discretionary 14.48%
4 Industrials 10.84%
5 Utilities 4.88%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GBT
76
DELISTED
Global Blood Therapeutics, Inc.
GBT
$3.8M 0.23%
165,000
– –
INCY icon
77
Incyte
INCY
$24.9B
$3.77M 0.23%
40,000
– –
VYGR icon
78
Voyager Therapeutics
VYGR
$189M
$3.6M 0.22%
300,000
– –
ACRS icon
79
Aclaris Therapeutics
ACRS
$743M
$3.58M 0.22%
+140,000
New +$2.97M
TCON
80
DELISTED
TRACON Pharmaceuticals, Inc. Common Stock
TCON
$3.5M 0.21%
2,589
– –
KA
81
DELISTED
Kineta, Inc. Common Stock
KA
$3.43M 0.21%
1,571
+142
+10% +$264K
LKFT
82
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.81B
$3.36M 0.21%
52,000
– –
RGEN icon
83
Repligen
RGEN
$7.03B
$3.32M 0.2%
110,000
– –
CDTX
84
DELISTED
Cidara Therapeutics
CDTX
$3.02M 0.18%
13,200
– –
VRTX icon
85
Vertex Pharmaceuticals
VRTX
$122B
$3.02M 0.18%
34,600
– –
NTUS
86
DELISTED
Natus Medical Inc
NTUS
$2.95M 0.18%
75,000
– –
ATRC icon
87
AtriCure
ATRC
$2.04B
$2.85M 0.17%
180,000
– –
AGTC
88
DELISTED
Applied Genetic Technologies Corporation
AGTC
$2.73M 0.17%
279,100
– –
EPZM
89
DELISTED
Epizyme, Inc
EPZM
$2.71M 0.17%
275,000
– –
JUNO
90
DELISTED
Juno Therapeutics, Inc.
JUNO
$2.7M 0.16%
90,000
– –
DVAX
91
DELISTED
Dynavax Technologies
DVAX
$2.62M 0.16%
250,000
– –
CTMX icon
92
CytomX Therapeutics
CTMX
$714M
$2.35M 0.14%
150,000
– –
TTPH
93
DELISTED
Tetraphase Pharmaceuticals, Inc.
TTPH
$2.3M 0.14%
30,000
– –
DRNA
94
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$2.22M 0.14%
377,000
– –
MCRB icon
95
Seres Therapeutics
MCRB
$46.3M
$2.19M 0.13%
8,910
– –
OMED
96
DELISTED
OncoMed Pharmaceuticals, Inc.
OMED
$2.17M 0.13%
190,000
– –
TNDM icon
97
Tandem Diabetes Care
TNDM
$1.3B
$2.11M 0.13%
27,500
– –
SYRS
98
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$2.08M 0.13%
15,000
– –
ARAY icon
99
Accuray
ARAY
$33.9M
$1.95M 0.12%
306,200
– –
SEP
100
DELISTED
Spectra Engy Parters Lp
SEP
$1.4M 0.09%
32,000
+14,800
+86% +$683K
2 3
4
5 6

Similar funds

HPG
Harvest Portfolios Group Oakville, Ontario, Canada $6.06B AUM 16.63% 1-Year Est. Return
EMPI
Elo Mutual Pension Insurance Espoo, Finland $6.06B AUM 24.33% 1-Year Est. Return
RCG
Ruane, Cunniff & Goldfarb New York $6.03B AUM 12.06% 1-Year Est. Return
JWBC
John W. Bristol & Co New York $6.08B AUM 16.51% 1-Year Est. Return
AAM
Advisors Asset Management Monument, Colorado $6.01B AUM 24.74% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return
CM
CastleKnight Management New York $6B AUM 121.87% 1-Year Est. Return
CIS
Capital International Sarl Los Angeles, California $6.11B AUM 32.29% 1-Year Est. Return

Eventide Asset Management's Q3 2016 Portfolio in Review

As of Q3 2016, Eventide Asset Management held 138 positions worth $1.64B, up 0.23% from $1.63B the previous quarter. Its ten largest holdings account for 30% of the portfolio.

Eventide Asset Management withdrew a net $183M in Q3 2016, closing 13 positions and reducing 20 holdings. Its most notable exit was First Solar, an estimated $27.4M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 35% of assets, up from 31% a quarter earlier, followed by Technology and Consumer Discretionary.

Against the trend, Eventide Asset Management opened a new position in Acuity Brands worth $21.2M.

  • Eventide Asset Management's largest Q3 2016 buy was Acuity Brands: 80,000 shares worth $21.2M.
  • Eventide Asset Management added most to 8point3 Energy Partners LP in Q3 2016, an estimated $5.01M increase.
  • Eventide Asset Management's biggest Q3 2016 reduction was Celgene Corp, cutting an estimated $24.6M.
  • Eventide Asset Management fully exited First Solar in Q3 2016, selling an estimated $27.4M.
  • Eventide Asset Management's ten largest holdings make up 30% of its $1.64B portfolio in Q3 2016.
  • Eventide Asset Management opened 10 new positions and closed 13 in Q3 2016.
  • Eventide Asset Management's portfolio value rose 0.23% quarter-over-quarter to $1.64B.

Based on Eventide Asset Management's 13F filing for Q3 2016, filed 14 Nov 2016.